<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030771</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 16/00</org_study_id>
    <secondary_id>SWS-SAKK-16/00</secondary_id>
    <secondary_id>EU-20138</secondary_id>
    <nct_id>NCT00030771</nct_id>
  </id_info>
  <brief_title>Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients</brief_title>
  <official_title>Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to
      stop tumor cells from dividing so they stop growing or die. Radiation therapy uses
      high-energy x-rays to damage tumor cells. Giving chemotherapy with radiation therapy before
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
      removed. It is not yet known if chemotherapy plus radiation therapy is more effective than
      chemotherapy alone before surgery in treating non-small cell lung cancer.

      PURPOSE: This randomized phase III trial is studying docetaxel and cisplatin with or without
      radiation therapy to see how well they work when given before surgery in treating patients
      with stage IIIA non-small cell lung cancer that has spread to lymph nodes in the chest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this trial is to compare feasibility and efficacy of sequential
      neoadjuvant chemoradiotherapy with 44 Gy concomitant boost to neoadjuvant chemotherapy alone.

      Secondary objectives are to assess the value of PET in predicting pathological response and
      eventfree survival in stage IIIA NSCLC, and a health economic analysis of the two regimens.
      Further to compare the amount of serum DNA in patients with stage IIIA, pN2 NSCLC before
      chemotherapy, before surgery and at the second follow-up visit (i.e. four months after
      surgery or treatment failure for patients who can not be operated) in patients randomized
      into the trial SAKK 16/00 and to correlate the DNA variation with tumor response, remission
      duration and overall survival.

      OUTLINE: This is a prospective randomized phase III trial. Patients are stratified according
      to mediastinal bulk (5 cm or more vs less than 5 cm), weight loss in the past 6 months (5% or
      more vs less than 5%), and participating center. Patients are randomized to 1 of 2 treatment
      arms.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 4, 2001</start_date>
  <completion_date type="Anticipated">December 2037</completion_date>
  <primary_completion_date type="Actual">April 9, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Time from randomization to relapse/progression/second tumor/death, whichever occurs first (for all randomized patients). If no event is observed, the patients will be censored at the last time they were known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality assessed</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>All deaths occurring within 30 days of the thoracic surgery to remove the primary tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>During treatment</time_frame>
    <description>Assessed according to the NCIC-CTG Expanded Common Toxicity Criteria grading. Special attention shall be given to hematological, renal and neurological toxicities, nausea and vomiting, weight changes as well as esophageal toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resection rate after surgery</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Assessed according to the NCIC-CTG Expanded Common Toxicity Criteria grading.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate measured after completion of chemoradiotherapy</measure>
    <time_frame>43 days</time_frame>
    <description>Response rate will be evaluated according to the
WHO response criteria
TNM classification after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operability</measure>
    <time_frame>1 month after chemo</time_frame>
    <description>Patients who are able to undergo radical resection of their lung cancer after neoadjuvant therapy, as assessed by the thoracic surgeon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Life-long follow-up until death of patient (up to 30 years)</time_frame>
    <description>Calculated from randomization to the date of death from any cause. Patients not experiencing an event will be censored at the last time they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure pattern</measure>
    <time_frame>Life-long follow-up until death of patient (up to 30 years)</time_frame>
    <description>Defined as location of first tumor progression or relapse. Failure can be local relapse (area of primary tumor or mediastinum), distant relapse (all others) or the combination thereof.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant Chemoradiotherapy + Chemotherapy + Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant Chemotherapy + Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>3-4 weeks after termination of radiotherapy</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer

               -  Squamous, adenosquamous, large cell, or poorly differentiated

          -  Stage IIIA (T1-3, N2, M0)

               -  N2 disease confirmed by 1 of the following:

                    -  Mediastinoscopy

                    -  Bronchoscopy with fine-needle aspiration or esophagoscopy

                         -  All N3 lymph nodes must be negative by positron-emission tomography
                            (PET) AND CT scan (&lt; 1 cm in the largest diameter)

                    -  PET scan

                         -  Both the primary tumor and at least 1 N2 lymph node must be positive in
                            PET scan

                         -  At least 1 of the PET scan positive N2 lymph nodes is positive in the
                            CT scan (&gt; 1 cm in the largest diameter)

                         -  All N3 lymph nodes negative in PET scan

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 75

        Performance status:

          -  WHO 0-1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 4,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin normal

          -  AST/ALT no greater than 1.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase no greater than 2.5 times ULN

        Renal:

          -  Creatinine clearance greater than 60 mL/min

        Cardiovascular:

          -  Cardiac function normal

          -  No unstable cardiac disease requiring treatment

          -  No congestive heart failure

          -  No angina pectoris even if medically controlled

          -  No significant arrhythmia

          -  No myocardial infarction in the past 3 months

        Pulmonary:

          -  Lung function appropriate

        Neurologic:

          -  No history of significant neurologic or psychiatric disorders

          -  No psychotic disorders

          -  No dementia

          -  No seizures

        Other:

          -  No other prior or concurrent malignancies except nonmelanoma skin cancer, adequately
             treated carcinoma in situ of the cervix, or any other neoplastic disease with a
             disease-free interval ≥ 5 years

          -  No active uncontrolled infection

          -  No uncontrolled diabetes mellitus

          -  No gastric ulcers

          -  No pre-existing peripheral neuropathy greater than grade 1

          -  No contraindications to corticosteroids

          -  No other serious underlying medical condition that would preclude study participation

          -  No socioeconomic or geographic condition that would preclude study participation

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior cytostatic chemotherapy

        Endocrine therapy:

          -  No concurrent prednisone except for treatment of acute hypersensitivity reactions or
             chronic low-dose treatment initiated more than 6 months prior to study entry (i.e., no
             greater than 20 mg methylprednisolone or equivalent)

        Radiotherapy:

          -  No prior radiotherapy to chest

        Surgery:

          -  Not specified

        Other:

          -  At least 30 days since participation in another clinical study

          -  No other concurrent experimental drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miklos Pless, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Winterthur KSW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans-Beat Ris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diana Naehrig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsspital-Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Stupp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudoise</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik Loewenstein gGmbH</name>
      <address>
        <city>Löwenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut za plucne bolesti</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Pluridisciplinaire d' Oncologie</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FMH Onkologie/Haematologie</name>
      <address>
        <city>Rheinfelden</city>
        <zip>4310</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum</name>
      <address>
        <city>Zurich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Serbia</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Tieu BH, Sanborn RE, Thomas CR Jr. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement. Thorac Surg Clin. 2008 Nov;18(4):403-15. doi: 10.1016/j.thorsurg.2008.07.004. Review.</citation>
    <PMID>19086609</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

